Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 04, 2015 4:51 AM ET


Company Overview of Liquidia Technologies, Inc.

Company Overview

Liquidia Technologies, Inc., a nanotechnology company, designs, develops, and manufactures precisely engineered particles and films for applications in life and materials science sectors. It develops micro and nanoparticles for the delivery of biological and small molecule therapeutics, as well as for the development of vaccines and inhaled therapeutics in the life sciences sector. The company also develops nano-patterned optical films for displays, lighting, photovoltaics, and related applications in the material science sector. Liquidia Technologies, Inc. was founded in 2004 and is based in Research Triangle Park, North Carolina.

419 Davis Drive

Suite 100

Morrisville, NC 27560

United States

Founded in 2004





Key Executives for Liquidia Technologies, Inc.

Chief Executive Officer and Director
Age: 53
Co-Founder and Senior Scientist
Chief Financial Officer
Compensation as of Fiscal Year 2015.

Liquidia Technologies, Inc. Key Developments

Liquidia Technologies, Inc. Presents at CED Life Science Conference 2015, Mar-04-2015 11:15 AM

Liquidia Technologies, Inc. Presents at CED Life Science Conference 2015, Mar-04-2015 11:15 AM. Venue: Raleigh Convention Center, Raleigh, North Carolina, United States. Speakers: Neal F. Fowler, Chief Executive Officer and Director.

Liquidia Announces Formation of Lq3 Pharmaceuticals

Liquidia Technologies announced the formation of a new pharmaceutical company, Lq3 Pharmaceuticals, dedicated to advancing novel therapies for oral health conditions. Leveraging the PRINT(R) (Particle Replication In Non-Wetting Templates) technology, Lq3 will initially focus on research and preclinical development of a lead, but currently undisclosed oral health product candidate. Like Envisia Therapeutics, Lq3 will leverage the transformative PRINT technology, a micro- and nanoparticle development and manufacturing platform known for its unique ability to control particle size, shape and chemistry. The PRINT technology provides a basis for the creation of innovative products that have the potential to address significant unmet needs in a wide range of medical conditions.

Similar Private Companies By Industry

Company Name Region
Taiga Biotechnologies, Inc. United States
Target Cancer Therapy, Inc. United States
Prism Ventures, LLC United States
CIMA Biotechnology Inc United States
Gemmus Pharma Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Liquidia Technologies, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at